Home page > Article
|
Previous article
|
Next article
SEARCH
QUICKLINKS AND VIEW OPITONS
Acomplia (rimonabant) side effects: nausea, dizziness, and upper respiratory tract infections
Posted by .(JavaScript must be enabled to view this email address)
Friday, March 11, 2005 2:46 pm Email this article
The most frequent side effects from Acomplia (rimonabant) are nausea, dizziness, and upper respiratory tract infections. Diarrhea: 2.3% vs 5.8% vs 7%
Diarrhea was more common as the dose of Acomplia (rimonabant) increased:
- 2.3 percent of patients given a placebo reported diarrhea compared to
- 5.8 percent given 5 mg of Acomplia (rimonabant) per day versus
- 7 percent of patients given 20 mg per day.
Nausea: 3.2% vs 7.2% vs 12.7%
Nausea was more common as the dose of Acomplia (rimonabant) increased:
- 3.2 percent of patients given a placebo reported nausea compared to
- 7.2 percent given 5 mg of Acomplia (rimonabant) per day versus
- 12.7 percent of patients given 20 mg per day.
Dizziness: 6.7% vs 8.4% vs 10.4%
Acomplia (rimonabant) caused more dizziness than placebo:
- 6.7 percent of patients given a placebo reported feeling dizzy compared to
- 8.4 percent given 5 mg of Acomplia (rimonabant) per day versus
- 15.7 percent of patients given 20 mg per day.
Upper respiratory tract infections: 5.7% vs 11.1% vs 10%
Acomplia (rimonabant) caused more upper respiratory tract infections than placebo:
- 5.7 percent of patients given a placebo developed upper respiratory tract infections compared to
- 11.1 percent given 5 mg of Acomplia (rimonabant) per day versus
- 10 percent of patients given 20 mg per day.
Dropouts due to side effects twice as common as placebo
The number of patients given Acomplia who have dropped out of studies due to side effects is about twice that of patients given a placebo.
In one study, 15 percent of patients given 20 mg of Acomplia per day dropped out due to side effects compared to 8.4 percent given 5 mg per day versus 7 percent in the placebo group.
In another study, 6.9 percent of patients given 20 mg of Acomplia per day dropped out due to side effects compared to 5.7 percent given 5 mg per day versus 3.8 percent in the placebo group.
REFERENCE
Boyd S, Fremming B. Rimonabant-a selective cb1 antagonist (april). Ann Pharmacother. 2005 Mar 8.
AUTHOR’S CORRESPONDENCE
School of Pharmacy and Health Professionals
Creighton University
Omaha, NE, USA
Articles on the same subject can be found here:
COMMENTS
On Mar 20, 2005 at 4:00 am Lisa wrote:
. . . . .
For what it's worth, I recently read in a women's magazine that Acomplia is expected on the market in early 2006 based on current FDA proceedings for its approval.
I was concerned, however, when another magazine said one of its side effects is depression. I don't see anything about that in this article. Has anyone learned anything else about this?
Thanks!
On Mar 20, 2005 at 5:44 am Larry Hobbs wrote:
. . . . .
Lisa,
Thank you for your input about the possible approval date for Acomplia.
Regarding Acomplia causing depression...
Although it is certainly possible, I have not seen this mentioned in any of the articles that I have read.
The paper summarized above, specifically states:
"Rates of anxiety and depression were not increased versus placebo in [one of the large Acomplia studies]." (Boyd and Fremming, 2005, p. 689, col. 2, top)
However, I did see a study on rats which stated that large doses of the drug seemed to increase anxiety. (How do you measure anxiety in rats? I don't know.)
Please feel free to share your comments about this article.
© Copyright 2003-2021 - Larry Hobbs - All Rights Reserved.